Planned Parenthood of N.Y.C., Inc. v. U.S. Dep't of Health & Human Servs.
Planned Parenthood of N.Y.C., Inc. v. U.S. Dep't of Health & Human Servs.
Opinion of the Court
*314I. INTRODUCTION
Plaintiff Planned Parenthood of New York City, Inc. ("PPNYC") challenges the issuance by the U.S. Department of Health and Human Services ("HHS") of two Funding Opportunity Announcements (the "2018 FOAs") that describe the terms whereby applicants can seek grant funding under the Teen Pregnancy Prevention ("TPP") Program. Plaintiff moves for summary judgment under Fed. R. Civ. P. 56(a), and seeks either a permanent injunction preventing defendants from implementing the FOAs or a preliminary injunction pursuant to Section 705 of the Administrative Procedure Act ("APA") and Fed. R. Civ. P. 65. Defendants move to dismiss for lack of standing under Fed. R. Civ. P. 12(b)(1), and cross-move for summary judgment.
The governing statute for the TPP Program establishes requirements for two tiers of grants: Three-quarters of the funding is allotted to Tier 1 Grants, which are for "replicating programs that have been proven effective through rigorous evaluation to reduce teenage pregnancy." The other quarter is designated for Tier 2 Grants to "develop, replicate, refine, and test additional models and innovative strategies for preventing teenage pregnancy." Applications for both tiers of grants are solicited through FOAs.
Plaintiff has been the beneficiary of TPP funding since the Program's inception in 2010, but alleges that it is now ineligible for and can no longer compete for Tier 1 and Tier 2 grants as a result of new FOAS adopted by HHS that it contends are contrary to law and arbitrary and capricious. We first address whether plaintiff has standing to challenge HHS's actions, and conclude that it does. We then consider whether the matter is committed to agency discretion and therefore unreviewable, and conclude that it is not. Next, we find that the adoption of the FOAs constitutes final agency action.
Having resolved these threshold issues, we turn to the merits. We hold that the 2018 Tier 1 FOA is contrary to the applicable statute because the evaluative tools that applicants for Tier 1 grants must "replicat[e]" are not "programs" and have not "been proven effective through rigorous evaluation." We reach a different conclusion as to the 2018 Tier 2 FOA because these tools and HHS's "public health priorities" are not inconsistent with Tier 2's statutory mandate to "test additional models and innovative strategies." Accordingly, we grant plaintiff's motion for summary judgment in part and permanently enjoin defendants from using the 2018 Tier 1 FOA as the basis for awarding or disbursing TPP Program funds, and grant defendants' motion for summary judgment as it relates to the 2018 Tier 2 FOA.
II. BACKGROUND
The relevant facts of this case are largely uncontested; we will note any facts in dispute.
*315Since 2010, Congress has annually allocated funding to HHS for "grants to public and private entities to fund medically accurate and age appropriate programs that reduce teen pregnancy." Consolidated Appropriations Act, 2018, Pub. L. No. 115-141,
HHS has solicited applications for TPP grants through FOAs, released in 2010, 2015, and as at issue here, 2018. The 2010 Tier 1 FOA identified 28 evidence-based programs that independent research by Mathematica Policy Research ("Mathematica") had shown to be effective.
The 2010 Tier 2 FOA called for applications "that propose to study a broad range of approaches to teenage pregnancy prevention," even if they had not previously been rigorously evaluated, with a particular focus on grants to programs "that *316clearly explain the potential to demonstrate evidence and which could eventually be replicated." 2010 Tier 2 FOA, Torrance Decl. Ex. B at 7-8, ECF No. 46-2.
In 2010, plaintiff was awarded a five-year Tier 1 grant of $611,823 annually to replicate one of the 28 evidence-based programs, "Making Proud Choices!," in schools, after-school programs, and community-based organizations in Manhattan, Brooklyn, and the Bronx. Compl. ¶ 87; 56.1 Stmt. ¶ 48; Barnette Decl. ¶ 9, ECF No. 39; Barnette Decl. Ex. C, ECF No. 39-3. In 2013, plaintiff received $262,541 in supplemental funding to expand to Queens. Compl. ¶ 87; 56.1 Stmt. ¶ 49. Plaintiff represents that it targeted 37 low-income and high pregnancy rate zip codes and reached 6,200 young people over the course of this five-year grant. Compl. ¶ 87.
HHS issued its second set of FOAs in 2015, splitting Tier 1 into two parts. Tier 1A focused on "Capacity Building to Support Replication of Evidence-Based Teen Pregnancy Prevention Programs," while Tier 1B focused on "Replicating Evidence-Based Teen Pregnancy Prevention Programs to Scale in Communities with the Greatest Need." See Barnette Decl. Ex. E, ECF No. 39-5; Barnette Decl. Ex. F, ECF No. 39-6. The 2015 Tier 1B FOA listed 36 evidence-based programs that had been designated as implementation ready and eligible for replication. 2015 Tier 1B FOA at 95-100, Barnette Decl. Ex. F at 98-103, ECF No. 39-6. In order to qualify, these programs needed to "1. Have been identified as having evidence of effectiveness by the HHS TPP Evidence Review ... and 2. Have been assessed by the HHS TPP Evidence Review as being implementation ready, meaning that the program has clearly defined curricula and components, necessary staff supports and training, and specified guidelines and tools for monitoring fidelity." Id. at 14-15.
Tier 2 was split into three sub-categories under the 2015 FOAs
In 2015, plaintiff submitted an application for Tier 1B funding, but was not selected as a grantee. 56.1 Stmt. ¶ 50; Barnette Decl. ¶ 14, ECF No. 39. However, since 2016, plaintiff has received annual funding as a sub-grantee of Texas A & M University's Integrating Teen Pregnancy Prevention Innovative Practices project, which had been awarded a Tier 2A grant. 56.1 Stmt. ¶ 51; Barnette Decl. ¶ 15, ECF No. 39; Barnette Decl. Ex. I, ECF No. 39-9; Barnette Decl. Ex. J, ECF No. 39-10.
Plaintiff represents that the current administration has taken several steps to "dismantle" the TPP Program. Compl. ¶¶ 54-64. First, in May 2017, HHS's proposed *317budget sought to eliminate all funding for the the TPP Program. Compl. ¶ 55 (citing HHS, General Departmental Management Budget at 91, https://www.hhs.gov/sites/default/files/combined-general-departmentmanagement.pdf). On March 23, 2018, however, Congress allocated $101 million to the TPP Program in the 2018 CAA. Compl. ¶ 62. Second, in July 2017, HHS announced that it would be terminating all TPP Program grants in June 2018, two years before their scheduled end date. Compl. ¶ 61. Various grantees filed four separate lawsuits, each of which was resolved in their favor. Id. (citing Planned Parenthood of Greater Wash. & N. Idaho v. HHS, No. 18 Civ. 55 (TOR),
On May 8, 2018, HHS issued the 2018 FOAs, the subject of this lawsuit. See TPP FY 18 Tier 1 FOA at AR000111; TPP FY Tier 2 FOA at AR000199. The Tier 1 FOA "solicit[s] applications ... to replicate and scale up one of two programs that include the protective factors shown to be effective in preventing teen pregnancy and/or sexual risk behaviors with youth." TPP FY 18 Tier 1 FOA at AR000034. The two referenced "programs" are the Tool to Assess the Characteristics of Effective Sex and STD/HIV Education Programs (the "TAC") and the Systematic Method for Assessing Risk-Avoidance Tool (the "SMARTool").
The SMARTool "describes 9 elements essential for effective sexual risk avoidance
Likewise, the TAC "describes 17 elements of effective sexual risk reduction
All applicants for both tiers of funding must also describe how they will emphasize HHS's "public health priorities," including that they promote the goal of "optimal health," "clearly communicate that teen sex is a risk behavior," "place a priority on providing information and practical skills to assist youth in successfully avoiding sexual risk," and "provide cessation support ... for those engaged in sexual risk."
The 2018 FOAs call for an independent review panel to evaluate, comment on, and score applications, and the Director of the Office of Adolescent Health to make final award selections to be recommended to the Grants Management Officer for risk analysis.
Plaintiff took part in initial informational calls with HHS regarding TPP Program funding and corresponded with HHS's "Tier 2 FOA Team" regarding specific requirements of applying under the 2018 FOAs. Barnette Decl. ¶ 23, ECF No. 39; Barnette Decl. Ex. M, ECF No. 39-13. Plaintiff decided not to apply for funding, representing that it takes significant resources to complete applications and that it cannot compete for funding under these FOAs. Barnette Decl. ¶¶ 41-50, ECF No. 39.
On June 22, 2018, one week before applications for funding under the 2018 FOAs were due, PPNYC filed this lawsuit. Compl., ECF No. 1. PPNYC filed a motion for summary judgment and sought a preliminary or permanent injunction preventing defendants from implementing the FOAs. Pl.'s Notice of Mot., July 24, 2018, ECF No. 32. Defendants moved to dismiss for lack of standing and filed a cross-motion for summary judgment. Defs.' Notice of Mot., Aug. 2, 2018, ECF No. 45. A brief was filed by twenty members of Congress as amici curiae represented by pro bono counsel (Boris Bershteyn, Mollie Kornreich, Tansy Woan, Micah Fergenson, and Natalie Gabrenya) in support of plaintiffs. Br., July 27, 2018, ECF No. 38-1. The parties requested that the Court issue a decision in this case no later than September 5, 2018. Accordingly, the Court ordered an expedited briefing schedule, which was completed on August 16, 2018. See Order, July 17, 2018, ECF No. 24.
III. DISCUSSION
A. Standing
Before turning to the merits, "we are required to assure ourselves of jurisdiction." Am. Atheists, Inc. v. Port Auth. of N.Y. & N.J.,
The irreducible constitutional minimum of standing consists of three elements: injury in fact, causation, and redressability. Lujan,
Defendants argue that this case should be dismissed because plaintiffs have failed to properly assert injury in fact and redressability.
1. Injury in Fact
Defendants begin by arguing that plaintiff has not established an injury in fact because it did not apply for funding under the 2018 FOAs. "To establish injury in fact, a plaintiff must show that he or she suffered an invasion of a legally protected interest that is concrete and particularized and actual or imminent, not conjectural or hypothetical." Spokeo,
Plaintiff asserts that its injury in fact is its inability to compete on an equal footing under the 2018 FOAs, while defendants reply that plaintiff was required to actually submit a bid for funding under the 2018 FOAs in order to have suffered a cognizable injury in fact. Defendant's position is not supported by the case law. Rather, to establish an injury in fact, a plaintiff "need only demonstrate that it is able and ready to bid on contracts," and is prevented from doing so on an equal basis by a government policy. Ne. Fla. Chap. of Assoc. Gen. Contractors of Am. v. City of Jacksonville,
Plaintiff here asserts that its core mission consists of providing sexual and reproductive health care and health education, including by providing community education and training to teens through community-based partnerships and in schools. Barnette Decl. ¶¶ 1, 3-5, ECF No. 39. To accomplish its mission, plaintiff researches the requirements of public and private grants, applies for appropriate grants, develops and tests new and innovative programs, and implements existing evidence-based programs.
Consistent with its mission and practice, plaintiff has bid for TPP funding at every opportunity since the TPP Program was established in 2010 until now. In 2010, plaintiff successfully bid on a five-year Tier 1 grant to replicate the "Making Proud Choices!" program in schools, after-school programs, and community-based organizations in Manhattan, Brooklyn, Queens, and the Bronx. Compl. ¶ 87; 56.1 Stmt. ¶¶ 48-49. Plaintiff bid again for funding under the 2015 FOAs. While plaintiff's bid for Tier 1B funding was initially unsuccessful, plaintiff sought to continue participating in the TPP Program, and eventually received funding as a sub-grantee of another *321project that had been awarded a Tier 2A grant. 56.1 Stmt. ¶¶ 50, 51.
Plaintiff represents that it was interested in bidding for another grant when the 2018 FOAs were first announced. Barnette Decl. ¶ 23, ECF No. 39. Specifically, plaintiff considered applying for a Tier 1 Grant to replicate the "Power Through Choices" curriculum, which is designed for teens in foster care and juvenile justice centers, as well as an evaluation of its "Adult Role Models" program for funding under a Tier 2 Grant. Barnette Decl. ¶ 24, ECF No. 39. Plaintiff's staff participated in informational calls with HHS, and plaintiff's Director of Private and Public Funding exchanged correspondence in May 2018 with HHS's "Tier 2 FOA Team" regarding the logistics of the summative outcome evaluation and developmental implementation evaluation as described in the 2018 FOAs. Barnette Decl. ¶ 23, ECF No. 39; Barnette Decl. Ex. M, ECF No. 39-13. After analyzing the 2018 FOAs, plaintiff ultimately decided that its applications for funding could not compete under the 2018 FOAs. Barnette Decl. ¶¶ 25, 41-50, ECF No. 39.
Given plaintiff's mission, prior bidding history, and exploratory efforts to bid for funding under the 2018 FOAs, plaintiff has asserted specific facts sufficient to support its contention that it "very likely would have bid" absent HHS's allegedly unlawful actions. See MGM,
In an effort to avoid that conclusion, defendants reply primarily on MGM and Warth v. Seldin, cases where courts found injury in fact lacking where a supposedly potential bidder had "no concrete plans," MGM,
Warth v. Seldin involved a challenge by a group of developers to a zoning ordinance in Penfield, New York that they alleged arbitrarily and capriciously prevented them from building low- and moderate-cost housing in the town.
By contrast, plaintiff here has asserted more than mere interest in TPP Program funding. Plaintiff describes in some detail specific projects that it would have pursued with grants under the 2018 FOAs.
*322However, plaintiff maintains that unlawful aspects of the 2018 FOAs have made it unable to compete for such grants. Plaintiff's concrete plans for TPP funding are thus much more closely analogous to the plaintiffs in City of Jacksonville,
Defendants next contend that plaintiff lacks the "direct economic interest" required for a prospective bidder to assert injury in fact, citing Orion Tech., Inc. v. United States,
Defendants also rely on dissimilar Tucker Act cases to argue that plaintiff lacks standing because it failed to "exercise reasonable diligence in pursuing" legal remedies. See CGI Fed. Inc. v. United States,
2. Redressability
In order for redressability to be satisfied, "it must be likely that a favorable judicial decision will prevent or redress the injury." Summers v. Earth Island Inst.,
*323Friends of the Earth, Inc. v. Laidlaw Envtl. Servs.,
Plaintiff here seeks to declare the 2018 FOAs invalid and enjoin HHS from awarding funds thereunder. See Compl. ¶¶ 126-28. Defendants argue that this relief would not redress plaintiff's injuries because it "would not result in the receipt of any funds by non-applicants like PPNYC." Defs.' Mem. of Law at 14, Aug. 2, 2018, ECF No. 49. This argument clearly fails: where, as here, a plaintiff asserts a cognizable competitive injury, it may be redressed by eliminating the allegedly unlawful barrier to competition. See City of Jacksonville,
Even if we were to accept defendants' argument that plaintiff's injuries will not be completely redressed unless it actually receives TPP funds, restoring plaintiff to a position where it can better compete for such funds must at least constitute partial redress, which is all that is required for purposes of Article III standing. See Monsanto Co. v. Geertson Seed Farms,
Defendants next assert that redress is unavailable because if the 2018 FOAs were voided, "it would be impossible for HHS to draft and issue new FOAs, receive applications, process those applications, and issue new awards by the end of the fiscal year." Defs.' Mem. of Law at 14, Aug. 2, 2018, ECF No. 49. As discussed above, redressability simply does not require plaintiff to prove that it or any similarly situated entity will actually obtain funding. Moreover, plaintiff suggests that an injunction would not force defendants to leave their appropriation unspent. Rather, defendants have "numerous options," including using "the remaining funds to grant carryover requests *324for existing projects."
B. Committed to Agency Discretion
The APA embodies a " 'strong presumption' favoring judicial review of administrative action." Mach Mining, LLC v. E.E.O.C., --- U.S. ----,
Defendants rely on a narrow exception to the "strong presumption" of reviewability. See Salazar v. King,
Defendants point to no statutory language in the 2018 CAA that evinces Congressional intent to insulate the 2018 FOAs from judicial review. Instead, defendants inaccurately state that "[a]n agency's allocation of appropriated funds is typically committed to agency discretion," and "agencies' grant-award decisions are presumptively unreviewable." Defs.' Mem. of Law at 16-17, Aug. 2, 2018, ECF No. 49 (emphasis added). We first note that plaintiffs here are not challenging an allocation of appropriated funds or a grant-award decision, but rather the establishment of FOAs under which grants will be awarded. Even if we accept defendants' characterization of the challenged action, this argument is unpersuasive. While the Supreme Court has held that certain allocations of funds from lump-sum appropriations may be committed to agency discretion, this narrow exception does not "typically" or "presumptively" extend to all allocations of appropriated funds. See Lincoln,
The statutory text here clearly provides the Court with a "relevant statutory reference point." See
These restrictions on the use of funds set this case apart from those cited by defendants. The statutory text governing appropriations to the TPP Program differs markedly from that in Lincoln, which granted the Indian Health Service the broad authority "to expend such moneys as Congress may from time to time appropriate, for the benefit, care, and assistance of the Indians," 508 U.S. at 185,
We therefore join the other courts that have reached a consensus that the CAA creates meaningful standards such that judicial review of appropriations to the TPP Program is available under the APA. See Policy & Research, LLC v. U.S. Dep't of Health & Human Servs.,
C. Final Agency Action
Defendants next challenge whether this suit properly implicates "final agency action" that may be the subject of judicial review. See
Plaintiff argues that the relevant "action" is HHS's adoption of the 2018 FOAs, Pl.'s Reply at 5, Aug. 9, 2018, ECF No. 50, while defendants posit that "the process PPNYC challenges is the awarding of grants," Defs.' Reply at 3, Aug. 16, 2018, ECF No. 53. This dispute can be resolved by examining the relief sought in the complaint: PPNYC seeks a declaration that the FOAs are ultra vires to the 2018 CAA and arbitrary and capricious, and further seeks to enjoin HHS from using the 2018 FOAs to review applications for TPP funding and from awarding or disbursing any funds pursuant to the 2018 FOAs. Compl. ¶¶ 126-128. Plainly, plaintiff has not challenged "the awarding of grants," which has not yet occurred. Rather, the "action" in question is the adoption and use of the 2018 FOAs, which plaintiff seeks to have declared illegal and enjoined.
We must next determine whether the adoption of the FOAs constituted "agency action," as that phrase is defined in
Having concluded that adopting the FOAs meets the definition of "agency action," we must next determine whether doing so constituted reviewable "final agency action." See
The Supreme Court and Second Circuit have repeatedly held that we must take a "pragmatic approach" to finality. Hawkes,
*328We therefore turn to the two criteria for "final agency action," beginning with the "consummation" prong. Our analysis of this prong is straightforward: Defendants do not and cannot contest that the version of the FOAs before the Court is subject to no further revision, and is by no means "tentative." See Bennett,
We reject defendants' contention that there can never be "consummation" in this context until an agency has actually issued grant awards. See, e.g., State ex rel. Becerra v. Sessions,
We therefore move to the second prong of our final agency action analysis - whether the challenged action is one by which rights or obligations have been determined or from which legal consequences will flow. See Bennett,
Under the 2018 Tier 1 FOA, a "[c]urriculum must be selected ... to address and replicate each of the elements in one of the two programs," and the FOAs definitively establish the two "programs" that an applicant for Tier 1 funding must replicate: the SMARTool and TAC. TPP FY 18 Tier 1 FOA at AR000034-35, AR000043-45. This structure creates "direct and appreciable consequences" for any applicant for TPP funding: The applicant must replicate one of these "programs." See Bennett,
Defendants assert that the FOAs do not immediately create legal consequences for the plaintiff because they do not implicate plaintiff's eligibility for funding. We disagree. Of course, the FOAs' "Application Disqualification Criteria" contain certain pro forma requirements, namely, whether an application is timely submitted and meets certain stylistic and page-limit requirements, whether an applicant is an institution rather than an individual, and whether the request for funding is within a defined range. See TPP FY 18 Tier 1 FOA at AR000058-62; TPP FY 18 Tier 2 FOA at AR000151-54. Significantly, under "Other Eligibility Information," the 2018 Tier 1 FOA states that it will "eliminate [an application] from the competition and it will not be reviewed" unless "one of the two eligible programs," SMARTool or TAC, "is clearly identified" for replication. TPP FY 18 Tier 1 FOA at AR000060; see also TPP FY 18 Tier 2 FOA at AR000152-53.
Thus, an applicant interested in replicating any other "program" is not eligible to receive funding. HHS's decision to predicate eligibility for funding on replicating either the SMARTool or TAC "directly affects" plaintiff. See Salazar,
Becerra and City of Philadelphia, involving challenges filed by the State of California and the City of Philadelphia against the Department of Justice ("DOJ") for imposing immigration-related conditions on the receipt of certain grants, are particularly analogous here. California and Philadelphia each filed suit after DOJ announced that it was imposing these conditions, but before DOJ had awarded the grants. DOJ therefore argued that there had been no final agency action because it had not yet determined whether these plaintiffs met these conditions, nor whether plaintiffs would actually receive any funding. Becerra,
Defendants next argue that plaintiff actually "preemptively challenge[s]" the independent review panels' application of the scoring criteria in the 2018 FOAs, and that these panels' scores "amount to nothing more than recommendations" to the OAH Director, who is responsible for final award selections. Defs.' Mem. of Law at 16, Aug. 2, 2018, ECF No. 49 (citing TPP FY 18 Tier 1 FOA at AR000094; TPP FY 18 Tier 2 FOA at AR000183-84). This argument fails for at least two reasons. First, as discussed above, the challenged action here is the adoption of the FOAs, not the panel's scoring. See Compl. ¶¶ 126-28. Second, defendants do not and cannot argue that any further action is necessary from the OAH Director to decide which "programs" prospective applicants must replicate.
In any event, the facts of this case differ significantly from Dalton v. Specter,
* * *
We have addressed defendants' arguments on standing, agency discretion, and finality individually, but it is important to recognize the import of their acceptance writ large. Defendants assert that the agency has not yet reached a final decision, and plaintiff has suffered no injury, because no grants have yet been awarded. But, if grants do issue, defendants argue that plaintiff will have suffered no injury because plaintiff did not apply for any funding, because the awarding of grants is subject to agency discretion, and because defendants have proclaimed that the OAH Director's decisions are unappealable and unreviewable.
The Court recognizes that Congress may create a statutory scheme that has the effect of insulating administrative action from judicial review in certain circumstances where it does so explicitly, see
D. Merits
Plaintiff asserts four overlapping claims for relief, alleging that the 2018 FOAs are: (1) contrary to the 2018 CAA in violation of the APA,
1. 2018 Tier 1 FOA
a) Contrary to Law
Plaintiff first argues that the 2018 Tier 1 FOA conflicts with the statutory restrictions on the TPP Program and should therefore be held unlawful and set aside because it is "not in accordance with law" under
"It is well settled that an agency may only act within the authority granted to it by statute." Nat. Res. Def. Council v. Nat'l Highway Traffic Safety Admin.,
Under Skidmore v. Swift & Co.,
We begin, as we must, with the text of the statute. See, e.g., Landreth Timber Co. v. Landreth,
Provided further , That of the funds made available under this heading, $101,000,000 shall be for making competitive contracts and grants to public and private entities to fund medically accurate and age appropriate programs that reduce teen pregnancy and for the Federal costs associated with administering and evaluating such contracts and grants, of which not more than 10 percent of the available funds shall be for training and technical assistance, evaluation, outreach, and additional program support activities, and of the remaining amount 75 percent shall be for replicating programs that have been proven effective through rigorous evaluation to reduce teenage pregnancy, behavioral risk factors underlying teenage pregnancy, or other associated risk factors, and 25 percent shall be available for research *332and demonstration grants to develop, replicate, refine, and test additional models and innovative strategies for preventing teenage pregnancy: Provided further , That of the amounts provided under this heading from amounts available under section 241 of the PHS Act, $6,800,000 shall be available to carry out evaluations (including longitudinal evaluations) of teenage pregnancy prevention approaches: Provided further , That of the funds made available under this heading, $25,000,000 shall be for making competitive grants which exclusively implement education in sexual risk avoidance (defined as voluntarily refraining from non-marital sexual activity): Provided further , That funding for such competitive grants for sexual risk avoidance shall use medically accurate information referenced to peer-reviewed publications by educational, scientific, governmental, or health organizations; implement an evidence-based approach integrating research findings with practical implementation that aligns with the needs and desired outcomes for the intended audience; and teach the benefits associated with self-regulation, success sequencing for poverty prevention, healthy relationships, goal setting, and resisting sexual coercion, dating violence, and other youth risk behaviors such as underage drinking or illicit drug use without normalizing teen sexual activity: Provided further , That no more than 10 percent of the funding for such competitive grants for sexual risk avoidance shall be available for technical assistance and administrative costs of such programs ....
2018 CAA, 132 Stat. at 733.
After setting aside up to 10% of the $101,000,000 for program support activities, 75% of the remaining funds are allocated to so-called "Tier 1 Grants." These grants are "for replicating programs that have been proven effective through rigorous evaluation to reduce teenage pregnancy, behavioral risk factors underlying teenage pregnancy, or other associated risk factors." Id. (emphasis added). That is, the model "programs" to be "replicat[ed]" must "have been proven effective through rigorous evaluation," and applicants' proposed "programs" must "replicat[e]" these models.
The other 25% of the remaining funds are allocated to "Tier 2 Grants," which "shall be available for research and demonstration grants to develop, replicate, refine, and test additional models and innovative strategies for preventing teenage pregnancy." Id. (emphasis added). An additional $6,800,000 is allocated to "carry out evaluations (including longitudinal evaluations) of teenage pregnancy prevention approaches." Id. (emphasis added). The 2018 CAA thus sets out a multi-tiered approach where three-quarters of the funding is allocated to Tier 1 Grants for "replicating programs proven effective through rigorous evaluation," and one-quarter of the funding is set aside for developing and refining new programs and strategies under Tier 2, with additional funding provided for evaluations, and administrative support. Id.
Plaintiff argues that the 2018 Tier 1 FOA is in conflict with three aspects of the statutory text of the Tier 1 provisions of the 2018 CAA. We therefore first examine the meaning of "programs," followed by "replicating," and then "proven effective through rigorous evaluation." We then compare the statutory requirements to the two model "programs" selected for replication in the Tier 1 FOA.
"Program" is not defined in the 2018 CAA, so "we give the term its ordinary meaning."
*333Encino Motorcars, LLC v. Navarro, --- U.S. ----,
The term "replicate" means to "duplicate" or "repeat." See"Replicate," Merriam-Webster's Collegiate Dictionary (11th ed.), https://www.merriam-webster.com/dictionary/replicate; see also Lott v. Levitt,
The 2018 Tier 1 FOA requires applicants for grants to "replicate" one of two "programs": the SMARTool or the TAC. TPP FY 18 Tier 1 FOA at AR000043-44. But by their own descriptions, neither is a "program." The "Introduction" paragraph to the SMARTool describes it as "a research-based tool designed to help organizations assess, select, and implement effective programs and curricula that support sexual risk avoidance." SMARTool at AR001829 (emphasis added); see also
Similarly, the TAC is - by name - a "Tool to Assess the Characteristics of Effective Sex and STD/HIV Education Programs." Douglas Kirby, et al., "Tool to Assess the Characteristics of Effective Sex and STD/HIV Education Programs" ("TAC") at AR001894; see also
Defendants urge us not to take the SMARTool and TAC at their word when they explain that they are not "programs," and insist that the SMARTool and TAC meant something else by "programs" than Congress did when it drafted the 2018 CAA. Defendants make no attempt to explain how the SMARTool and TAC's usage of "programs" differed from Congress's. They merely assert that "there is no reason to equate Congress's use of the word 'program' in the TPP Program appropriation and private parties' use of the word in the documentation for the SMARTool or TAC programs." Defs.' Reply at 11, Aug. 16, 2018, ECF No. 53. This argument does not withstand scrutiny.
Of course, words may take on different meanings in different technical settings, and it is possible for Congress and a private party to use the same word in two different ways. See, e.g., Mac's Shell Serv., Inc. v. Shell Oil Prods. Co. LLC,
Rather, the SMARTool and TAC are evaluative tools. And because they are modes of assessment, they are not readily "replicabl[e]" into "programs."
Moreover, the SMARTool and TAC are not "programs" that have been "proven effective through rigorous evaluation." The term "rigorous evaluation" is not defined in the 2018 CAA. The plain meaning of "evaluate" is "to determine the significance, worth, or condition of usually by careful appraisal and study." "Evaluate," Merriam-Webster's Collegiate Dictionary (11th ed.), https://www.merriam-webster.com/dictionary/evaluate. And we must give meaning to Congress's use of "rigorous," such that a "program" must be "proven effective" by a particularly searching, "scrupulously accurate" evaluation. See Leocal v. Ashcroft,
We next consider how "rigorous evaluation" is used elsewhere in the same statute. See FDA v. Brown & Williamson Tobacco Corp.,
We also examine the way this phrase has been employed in similar statutes. See United States v. Sioux,
This interpretation is consistent with the structure of the 2018 CAA, which sets aside funding and creates multiple mechanisms to evaluate "programs" to determine if they have been proven effective. Most directly, $6,800,000 in funding is made available to "carry out evaluations." 2018 CAA, 132 Stat. at 733. Indeed, this funding has been used for the TPP Evidence Review, which, until the 2018 FOAs, provided the list of program "proven effective by rigorous evaluation." See 2010 Tier 1 FOA, Torrance Decl. Ex. A at 7, 38, ECF No. 46-1. Tier 2 is also structured to serve as a laboratory for Tier 1. The TPP Program sets aside Tier 2 funding to "develop, replicate, refine, and test additional models" - that is, ones that may not yet have been "proven effective" - and "innovative strategies" that, based on their novelty, have not yet been subject to "rigorous evaluation." 2018 CAA, 132 Stat. at 733. The statute thus contemplates that "programs" will prove their mettle, either through smaller Tier 2 grants or by other means of rigorous evaluation, before they can be eligible to serve as a model for programs that receive Tier 1 funding. Plainly, evaluative tools like the SMARTool and TAC have not been and cannot be evaluated by these means.
Our understanding of the 2018 CAA is further supported by its legislative history. See Disabled in Action of Metro. N.Y. v. Hammons,
*337model "programs" be "evidence-based" and backed by precise empirical evaluation.
Unsurprisingly, defendants do not point to any empirical study or analysis of the SMARTool or TAC in the administrative record. As the SMARTool and TAC are themselves evaluative tools, they cannot readily be subject to the types of rigorous testing expected of a Tier 1 model "program." Defendants argue instead that it was "rational" to select the SMARTool and TAC as model programs for Tier 1 funding based on their "promise." Defs.' Reply at 14, Aug. 16, 2018, ECF No. 53. But promise is no substitute for proof, which is what the statute requires. By requiring applicants to "replicate" the SMARTool and TAC, defendants have violated their statutory obligation to select model "programs" "proven effective through rigorous evaluation."
Having found that the 2018 Tier 1 FOA is contrary to law, it is not necessary to reach plaintiff's argument that the content of the 2018 Tier 1 FOA was improperly driven by defendants' policy priorities.
b) Arbitrary and Capricious
Plaintiff next argues that we must set aside the 2018 Tier 1 FOA because it represents arbitrary and capricious agency action in violation of
"Agencies are free to change their existing policies as long as they provide a reasoned explanation for the change." Id."There is no need, however for an agency to provide detailed justification for every change or to show that the reasons for the new policy are better than the reasons for the old one." F.C.C. v. Fox Television Stations, Inc.,
"Normally, an agency rule would be arbitrary and capricious if the agency has relied on factors which Congress has not intended it to consider, entirely failed to consider an important aspect of the problem, offered an explanation for its decision that runs counter to the evidence before the agency, or is so implausible that it could not be ascribed to a difference in view or the product of agency expertise." Pub. Citizen,
Defendants argue that their decision to install the SMARTool and TAC as the only two model "programs" in the 2018 Tier 1 FOA was justified by the fact that "internal and external sources have cast serious doubt on the efficacy of the agency's previous efforts to identify programs that can be effectively replicated in the TPP Program." Defs.' Mem of Law at 29, Aug. 2, 2018, ECF No. 49. Specifically, defendants identify the following evidence that they contend supports their decision: (1) three documents related to a study entitled "Meta-Analysis of Federally Funded Teen Pregnancy Prevention Programs," by Randall Juras, et al., dated November 2, 2017 (the "Juras Study"); (2) a press release entitled "Teen Pregnancy Prevention Program Facts," dated August 28, 2017 (the "TPP Program Press Release" or the "Press Release"); and (3) a report entitled "The Teen Pregnancy Prevention Program (2010-2015): Synthesis of Impact Findings," by Amy Feldman Farb and Amy L. Margolis, dated June 24, 2016. Defendants contend that these materials show that "quantitative analyses of individual program models fail[ed] to generate viable options for replication," such that it was reasonable to abandon the use of model "programs" altogether and instead turn to the SMARTool and TAC. Contrary to defendants' contentions, analysis of these materials makes clear that the agency had numerous "viable options" that complied with Tier 1's statutory requirements such that the adoption of the 2018 Tier 1 FOA, which did not comply with the statutory requirements, was arbitrary and capricious.
We begin with the Juras Study. The index of the Administrative Record submitted to the Court by defendants lists three documents associated with the Juras Study: (1) the Study itself; (2) a summary description of a presentation describing the findings of the Study at the Association for Public Policy Analysis & Management's ("APPAM") Fall Research Conference on November 2, 2017 ("the Juras Summary"); and (3) the presentation slides from the APPAM Conference (the "Juras Presentation").
The first of these documents, however, is not actually in the Administrative Record because defendants have withheld it from the Court and plaintiff, citing "deliberative process privilege." Administrative Record Index at 4 n.*, Aug. 2, 2018, ECF No. 47 ("Although the study described *339by this document is complete, the study report continues to undergo internal revision. Defendants thus withhold the document at this time pursuant to the deliberative process privilege.... Defendants will submit the full study paper to the Court and Plaintiffs when it is publicly available."). This document is entitled to no weight in our consideration for two independent reasons. First, we have no way of assessing a document that has been withheld from the Court.
The Juras Summary is equally unhelpful - it is less than a page long and focuses on the methodology rather than the conclusions of the Juras Study. See Panel Paper: Meta-Analysis of Federally-Funded Teen Pregnancy Prevention Programs (2017 APPAM Fall Research Conference) at AR000022. Defendants thus rely primarily on the Juras Presentation, a 14-page PowerPoint summarizing the Study's findings. See APPAM Presentation 2017 Meta-Analysis at AR000008-21. In particular, defendants point to a heading on the tenth slide of the Presentation that states there has been "No strong evidence that any program or individual characteristics affected outcomes."
We turn next to the TPP Program Press Release,
The parties dispute whether the results of the 2016 report described in the Press Release were "questionable," see Defs.' Reply at 14, Aug. 16, 2018, ECF No. 53, or "very strong," see Pl.'s Reply at 21, Aug. 26, 2018, ECF No. 50 (citing Link Decl. Ex. 5 at 3-5, Email from Evelyn Kappeler, Director of OAH (July 26, 2017), ECF No. 34 ("Cohort 1 data identified 12 TPP program models with demonstrated positive behavioral impacts at varying time points post program delivery.... The field considers the evidence from the TPP Cohort 1 evaluations to be very strong.") ). We need not resolve that dispute here. What this report inarguably shows is the "rigorous evaluation" process mandated by the statute at work. No matter how the data is spun by the parties, the report shows that at least some programs were "proven effective by rigorous evaluation." Even if the success rate did not meet defendants' expectations, that would not provide an "adequate reason" for defendants to abandon the statutory requirements of the TPP Program. See Encino, 136 S.Ct. at 2125.
Finally, defendants cite a report entitled "The Teen Pregnancy Prevention Program (2010-2015): Synthesis of Impact Findings," an exhibit submitted by plaintiff in this litigation that is not part of the Administrative Record. See Harker Decl. Ex. 9 at 526-32, ECF No. 37-1 at 526-32. Defendants cite to a finding in this report that only four of 19 Tier 1 programs from 2010 to 2015 had statistically significant positive behavioral impacts on any outcome measure. Our analysis of this report is the same as the Press Release. Its most relevant finding is that rigorous evaluation of TPP programs demonstrated that at least some programs reported statistically significant evidence of positive outcomes.
Notably absent and glaringly so from the Administrative Record is Mathematica Policy Research's latest TPP Evidence Review, published in April 2018. See Julieta Lugo-Gil et al., "Updated findings from the HHS Teen Pregnancy Prevention Evidence Review: August 2015 through October 2016" ("2018 Evidence Review"), Harker Decl. Ex. 18, ECF No. 37-3 at 130-161. In 2010, HHS contracted with Mathematica to provide it with periodic Evidence Reviews of the program models selected for the TPP Program. Compl. ¶ 33. Financial support for Mathematica's Evidence Review has come at least in part from the provision of the TPP Program providing funding "to carry out evaluations (including longitudinal evaluations) of teenage pregnancy approaches." Compl. ¶ 30; see 2010 CAA, 123 Stat. at 3253; 2018 CAA, 132 Stat. at 733. The 2018 Evidence Review, published the same week as the 2018 FOAs, identified four new programs that met its review criteria for evidence of effectiveness,
Plaintiff argues that it was arbitrary and capricious for defendants to ignore the 2018 Evidence Review. Defendants respond that the Juras Study and other materials cited above show that "very few" of the programs selected by the TPP Evidence Review actually yielded positive results. Defs.' Mem. of Law at 6, Aug. 2, 2018, ECF No. 49. But this counter-argument amounts to a concession that there were programs available that have been proven effective, including by the Juras Study itself. Even assuming that the Juras Study provided defendants with "a reasoned explanation" to no longer rely upon the TPP Evidence Review, it did not give them an "adequate reason" to flaunt the statutory requirement to "replicat[e] programs that have been proven effective through rigorous evaluation." See Encino, 136 S.Ct. at 2125 ; see also Hoag Mem. Hosp. Presbyterian v. Price,
2. 2018 Tier 2 FOA
The same infirmities identified above do not infect the 2018 Tier 2 FOA. We begin again with the text of the Tier 2 provision in the statute, which makes funding "available for research and demonstration grants to develop, replicate, refine, and test additional models and innovative strategies for preventing teenage pregnancy." 2018 CAA, 132 Stat. at 733. Unlike Tier 1, Tier 2 does not require proof of effectiveness nor faithfulness to a proven program. Rather, Congress's use of "develop, refine and test" all suggest experimentation. We define the fourth verb, "replicate," the same way as above, see Mathis v. S.E.C.,
Plaintiff does not argue that the 2018 Tier 2 FOA violates any portion of this statutory language, but rather points to the introductory clause of the TPP Program statute, which provides that any funding, even if it is used to develop an "innovative strategy," must be for "medically accurate and age appropriate programs that reduce teen pregnancy." 132 Stat. at 733. Plaintiff therefore asserts that the 2018 Tier 2 FOA is contrary to the statute because its "public health priorities" dictate that HHS will fund programs that are not "medically accurate." Pl.'s Reply at 20, Aug. 9, 2018, ECF No. 50. This argument fails as a matter of statutory structure. Tier 2's place in the TPP Program is the laboratory where applicants can test programs that might someday be eligible for replication in Tier 1. See Kantor Decl. ¶ 38, Aug. 9, 2018, ECF No. 52 ("The Tier 2 funding is designed to support new and innovative approaches to teen pregnancy prevention programs that do not have previous rigorous research demonstrating their effectiveness."). At this juncture, the Court cannot conclude as *342a matter of law that any program developed under the SMARTool or TAC and analyzed through the lens of the "public health priorities" would lack "medical accuracy." If HHS actually awards Tier 2 grants to applicants whose proposals are not medically accurate, that may be the basis for future litigation, but that issue is not currently before the Court.
The relevant distinction between the Tiers is statutory. While defendants are precluded from using evaluative tools like the SMARTool and TAC as a substitute for "programs proven effective through rigorous evaluation," they may use them to "develop and "test innovative strategies" under Tier 2. TPP FY 18 Tier 2 FOA at AR000137. Indeed, plaintiff argued that the 2018 Tier 1 FOA is contrary to law because it would improperly fund unproven programs that belonged in Tier 2. Pl.'s Mem. of Law at 21, July 24, 2018, ECF No. 36 ("The 2018 Tier 1 FOA also seeks to transfer the funding for Tier 1 into the Tier 2 appropriation."); Kantor Decl. ¶ 38, ECF No. 52 ("By shifting to an approach that allows applicants to create or choose a program with no previous rigorous evidence of effectiveness, the Tier 1 program has essentially been discontinued in favor of a Tier 2 approach...."). If relying on the SMARTool, TAC, and "public health priorities" in Tier 1 meant adopting "a Tier 2 approach," it logically follows that they were not improper considerations for Tier 2.
The same problems plague plaintiff's argument that the 2018 Tier 2 FOA is arbitrary and capricious. While defendants cannot rely on the SMARTool and TAC in violation of the statutory requirements of Tier 1, defendants adequately justify employing these tools to test novel approaches in an attempt to improve the Teen Pregnancy Prevention Program. Tier 2 serves as a laboratory for developing new model programs, and, in defendants' view, the SMARTool and TAC identify the "key elements of effective programs recognized by social science research to affect adolescent risk behaviors." TPP FY 18 Tier 2 FOA at AR000137. Nothing in the record suggests that these tools are so inherently flawed that it would be inappropriate to use them as a reference point in devising a grant proposal. Defendants need not demonstrate that this approach is better than the ones used for the 2010 and 2015 FOAs: "it suffices that the new policy is permissible under the statute, that there are good reasons for it, and that the agency believes it to be better, which the conscious change of course adequately indicates." Fox,
E. Remedies
A plaintiff seeking a permanent injunction must satisfy a four-factor test: "(1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, considering the balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction." Monsanto Co. v. Geertson Seed Farms,
These four factors all support granting an injunction here. As to irreparable harm, plaintiff has been injured based on its inability to compete under the 2018 FOAs.
*343See Int'l Franchise Ass'n, Inc. v. City of Seattle,
The final two factors merge when an injunction is to be issued against the government. See Pursuing Am.'s Greatness v. FEC,
IV. CONCLUSION
Plaintiff's motion for summary judgment is granted as to the 2018 Tier 1 FOA because the evaluative tools that applicants for Tier 1 grants must "replicat[e]" are not "programs" and have not "been proven effective through rigorous evaluation," as required by the statute. Plaintiff's motion for summary judgment is denied as to the 2018 Tier 2 FOA. Defendants' motion to dismiss is denied, and their cross-motion for summary judgment is denied as to the 2018 Tier 1 FOA and granted as to the 2018 Tier 2 FOA. Defendants are permanently enjoined from using the 2018 Tier 1 FOA as the basis for awarding or disbursing TPP Program funds. The Clerk of Court is respectfully directed to terminate the motions pending at ECF Nos. 32 and 45 and close this case.
SO ORDERED.
The factual background is largely drawn from the Administrative Record ("AR"), Aug. 2, 2018, ECF No. 47; Complaint, June 22, 2018, ECF No. 1; Plaintiff's 56.1 Statement, ECF No. 35 ("56.1 Stmt."); and the declarations of Marcus A. Asner, Aug. 9, 2018, ECF No. 51; Margaret Barnette, July 31, 2018, ECF No. 39; Drew A. Harker, July 24, 2018, ECF No. 37; Leslie M. Kantor, Aug. 9, 2018, ECF No. 52; Benjamin Link, July 24, 2018, ECF No. 34; and Benjamin H. Torrance, Aug. 2, 2018, ECF No. 46, and attached exhibits.
Defendants did not submit a 56.1 Statement, explaining that doing so would be inconsistent with "its usual practice in APA cases" and "neither necessary nor appropriate." Defs.' Mem. of Law at 10 n.4, Aug. 2, 2018, ECF No. 49.
From approximately 1,000 potentially relevant studies, Mathematica initially identified 28 programs with a documented, favorable, statistically significant impact on at least one sexual risk behavior or reproductive health outcome of interest (sexual activity, number of sexual partners, contraceptive use, STIs, or pregnancy). See Compl. ¶¶ 33-34; Br. of Members of Congress as Amici Curiae at 10, July 27, 2018, ECF No. 38-1.
Mathematica has continued to publish periodic "Evidence Reviews" of the program models selected for the TPP Program. Compl. ¶¶ 33, 43, 51. Until the 2018 FOAs, the programs eligible for replication under Tier 1 were drawn from the programs that had been proven effective according to Mathematica's Evidence Reviews. Id. ¶¶ 46-47. Mathematica's most recent Evidence Review brought the programs that met its criteria for evidence of effectiveness to 48. Id. ¶ 51.
The Complaint omits mention of Tier 2C, but plaintiff's later briefing acknowledges that there were five tiers of funding in the 2015 FOAs, not four. Compare Compl. ¶¶ 45-46 (discussing only Tiers 2A and 2B), with 56.1 Stmt. ¶ 15 ("The 2015 FOAs were further divided into Tier 1A/B and Tier 2A/2B/2C grants to provide more guidance to applicants and emphasize particular areas of need.").
Defendants state that "programs that promote abstinence" are "the most commonly discussed form of sexual risk avoidance," Defs.' Mem. of Law at 7, Aug. 2, 2018, ECF No. 49, while plaintiff asserts that abstinence-only education has been "rebrand[ed]" as "sexual risk avoidance," Compl. ¶ 58 (citing Mark Peters, Euphemism: Sexual Risk Avoidance, Boston Globe, June 23, 2017, https://www.bostonglobe.com/ideas/2017/06/23/euphemism-sexual-risk-avoidance/cowYjFTOcIS7hmD0wtm64O/story.html); see also Barnette Decl. ¶ 20 (stating "risk avoidance (also known as abstinence-only until marriage programs)"). The SMARTool itself uses sexual risk avoidance and abstinence education interchangeably. See The Center for Relationship Education, "SMARTool - Systematic Method for Assessing Risk-avoidance Tool" ("SMARTool") at AR001831, AR001833, AR001839.
The parties agree that plaintiff's programs are sometimes characterized as "sexual risk reduction programs." Defs.' Mem. of Law at 27, Aug. 2, 2018, ECF No. 49; Compl. ¶ 90 ("PPNYC's evidence-based, sexual risk reduction programming...."); Barnette Decl. ¶ 20, ECF No. 39 ("[R]isk reduction (what proponents of abstinence-only until marriage program [sic] call programs like ours)."). Plaintiff prefers to describe this approach as "comprehensive sex education." Compl. ¶¶ 60, 78, 84; 56.1 Stmt. ¶ 23; Pl.'s Mem. of Law at 4-5, July 24, 2018, ECF No. 36.
Indeed, acceptance of defendants' argument would serve to encourage an agency to structure its actions in a manner designed to "run out the clock."
This provision states in full:
§ 704. Actions reviewable
Agency action made reviewable by statute and final agency action for which there is no other adequate remedy in a court are subject to judicial review. A preliminary, procedural, or intermediate agency action or ruling not directly reviewable is subject to review on the review of the final agency action. Except as otherwise expressly required by statute, agency action otherwise final is final for the purposes of this section whether or not there has been presented or determined an application for a declaratory order, for any form of reconsideration, or, unless the agency otherwise requires by rule and provides that the action meanwhile is inoperative, for an appeal to superior agency authority.
The fact that defendants failed to raise this argument until the fourth and final brief on these cross-motions for summary judgment is alone dispositive. See Ct. Bar Ass'n v. United States,
" '[R]elief' includes the whole or a part of an agency - (A) grant of money, assistance, license, authority, exemption, exception, privilege, or remedy; (B) recognition of a claim, right, immunity, privilege, exemption, or exception; or (C) taking of other action on the application or petition of, and beneficial to, a person."
The question of whether the requirement of "final agency action" under
We note that the majority of courts and commentators have suggested that the Supreme Court's decisions in Arbaugh v. Y & H Corp.,
The parties have not briefed this issue, and it is not determinative of the result here. Plaintiff has met its burden under either the Rule 12(b)(1) or Rule 56(a) standard.
This fact also distinguishes this case from Planned Parenthood of Wisconsin, Inc. v. Azar,
The 2018 FOAs themselves purport to preclude any challenge to grants made thereunder: "All award decisions, including level of funding if an award is made, are final and you may not appeal." TPP FY 18 Tier 1 FOA at AR000094; TPP FY 18 Tier 2 FOA at AR000183.
Plaintiff does not demonstrate how its ultra vires claim differs in any meaningful way from its claim that the 2018 FOAs are contrary to law under the APA. The parties' briefing on the Anti-Deficiency Act claim is spare, and plaintiff does not argue in support of this claim in its reply brief. Under these circumstances, we may deem this claim to be abandoned. See, e.g., Phoenix Light Ltd. v. Bank of N.Y. Mellon, No. 14 Civ. 10104 (VEC),
Depending on the context, "replicating" may not be limited to making exact copies, see, e.g., Arborjet, Inc. v. Rainbow Treecare Sci. Advancements, Inc.,
We find it highly improbable that the developers of the SMARTool, who include the former director of family planning and abstinence education evaluation systems at HHS and a grants manager and research consultant at HHS, were unaware of how "program" was used in HHS's Teenage Pregnancy Program appropriations. SMARTool at AR001825-26; see also
Defendants argue that this failure to "replicat[e]" should be excused because the 2010 and 2015 FOAs also permitted programs that did not faithfully "replicat[e]" the selected program models. See Defs.' Mem. of Law at 20-21, Aug. 2, 2018, ECF No. 49. Specifically, defendants note that the earlier FOAs permitted applicants to make "adaptations ... to make the program more relevant to ethnic, racial or linguistic characteristics of the population to be served," and to "revis[e] materials to ensure LGBTQ inclusivity."
We are cognizant of the canon of construction that "[w]here Congress includes particular language in one section of a statute but omits it from another, it is generally presumed that Congress acts intentionally and purposely in the disparate inclusion or exclusion." See Russello v. United States,
While we do not rely on them in reaching this decision, amici also point us to other background documents that suggest the creation of the TPP Program was a key part of a broader emphasis by the Obama Administration on policy decisions based on "the rigorous use of performance data." Peter Orszag, Office of Management and Budget, "Building Rigorous Evidence to Drive Policy," https://obamawhitehouse.archives.gov/omb/blog/09/06/08/BuildingRigorousEvidencetoDrivePolicy/ (June 8, 2009) (describing Tier 1 of the TPP: "[W]e're using a similar, two-tiered approach. First, we're providing more money to programs that generate results backed up by strong evidence. That's the top tier. Then, for an additional group of programs, with some supportive evidence but not as much, we've said: Let's try those too, but rigorously evaluate them and see whether they work.") (emphasis added); see also Evelyn M. Kappeler (Director, OAH) and Amy Feldman Farb (Evaluation Specialist, OAH), "Historical Context for the Creation of the Office of Adolescent Health and the Teen Pregnancy Prevention Program," 54 Journal of Adolescent Health 53 (2014) (describing the TPP Program as one of the Obama Administration's "evidence-based social policy initiatives" that "utiliz[ed] evidence-based models").
Similarly, we need not address plaintiff's specific assertions that defendant Valerie Huber is biased in favor of abstinence-only education because she served as the abstinence education coordinator for the Ohio Department of Health from 2004 to 2007, formed the National Abstinence Education Association in 2007, and lobbied to eliminate the TPP Program before she was appointed Senior Policy Advisor for the Office of the Assistant Secretary for Health at HHS. See Compl. ¶¶ 56-60; Pl.'s Mem. of Law at 4-7, 19, July 24, 2018, ECF No. 36; Link Decl. Ex. 1 at 6-8, Ex. 2 at 8-10, ECF No. 34.
Withholding the document for "internal revision" in the midst of litigation also raises a question about the objectivity of the work product.
Driving home this point is the fact that in order for a document to be protected by the deliberative process privilege, it must be "pre-decisional." Tigue v. U.S. Dep't of Justice,
As some of the text of the version of the TPP Program Press Release in the Administrative Record at AR000029-31 is illegible, we have consulted the version of this Press Release posted on HHS's website at: https://www.hhs.gov/ash/about-ash/news/2017/teen-pregnancy-preventionprogram-facts.html.
The 2018 Evidence Review defines "evidence of effectiveness" as "evidence of at least one favorable statistically significant impact on at least one sexual risk behavior or reproductive health outcome of interest (sexual activity, number of sexual partners, contraceptive use, STIs, or pregnancy)." Harker Decl. Ex. 18, ECF No. 37-3. These measures of effectiveness are consistent with the statute, which allocates funds to programs that have "been proven effective through rigorous evaluation to reduce teenage pregnancy, behavioral risk factors underlying teenage pregnancy, or other associated risk factors." 132 Stat. at 733 (emphasis added).
Reference
- Full Case Name
- PLANNED PARENTHOOD OF NEW YORK CITY, INC. v. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Alex Michael Azar, II, in his official capacity as Secretary of the U.S. Department of Health and Human Services Valerie Huber, in her official capacity as Senior Policy Advisor for the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services
- Cited By
- 24 cases
- Status
- Published